Conference Coverage

‘Chemo brain’ may have targetable causes


 

References

Another genetic factor linked to postchemotherapy cognitive decline is the Val158Met polymorphism of the gene encoding for Catechol-O-methyltransferase (COMT), an enzyme that degrades neurotransmitters such as dopamine. Patients with this polymorphism have rapid dopamine metabolism, resulting in reduced dopamine activity.

These findings point to potential molecular mechanisms for cognitive changes associated with chemotherapy, and suggest that therapies targeted at neurotransmitter systems may ameliorate the effect, Dr. Ahles said.

He noted that animal studies have shown that fluoxetine (Prozac) prevents deficits in behavior and hippocampal function associated with 5-fluourauracil (5-FU), and that nicotine patches have been shown to improve cognitive functioning in patients with mild cognitive impairment.

The symposium was cosponsored by AAHPM, ASCO, ASTRO, and MASCC.

Pages

Recommended Reading

Long-term benzodiazepine use may contribute to risk of Alzheimer’s
MDedge Neurology
VIDEO: A fib screening finds 5% of elderly undiagnosed
MDedge Neurology
Vitamin D deficiency associated with Alzheimer’s
MDedge Neurology
Three-minute assessment detected most cases of delirium
MDedge Neurology
Novel anticoagulants increase GI bleeds in elderly
MDedge Neurology
Dengue, West Nile threaten to set up housekeeping in U.S.A.
MDedge Neurology
Clopidogrel seems safe in ischemic stroke with microbleeds
MDedge Neurology
ICU meds can bring on serotonin syndrome
MDedge Neurology
Decompression can save lives in ventricular trapping
MDedge Neurology
The dilemma of using drugs of questionable benefit
MDedge Neurology